References
- Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-62. doi: 10.2337/diacare.28.4.956.
- Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-4. doi: 10.1007/BF00400697.
- Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-88. doi: 10.2337/diacare.1.3.168.
- Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-10. doi: 10.1212/01.wnl.0000145767.36287.a1.
- Daniel SR, Badyal DK, Jacob JJ, Kaur J. Efficacy and safety of pregabalin versus amitriptyline in patients with painful diabetic neuropathy. Int J Adv Med. 2018;5:716-21. doi: 10.18203/2349-3933.ijam20182129.
- Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev.2019;1:CD007076. doi: 10.1002/14651858.CD007076.pub3.
- Ziegler D, Reljanovic M, Mehnert H, Gries FA.Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107:421-30. doi: 10.1055/s-0029-1212132.
- Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004;3:173-89. doi:10.2165/00024677-200403030-00005.
- Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34:2054-60. doi: 10.2337/dc11-0503.
- Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26:770-6. doi: 10.2337/diacare.26.3.770. Erratum in: Diabetes Care. 2003;26:2227.
- McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377-85. doi: 10.2147/TCRM.S11325.
- Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997;46 Suppl 2:S54-7. doi: 10.2337/diab.46.2.s54.
- Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014;12:44-56. doi: 10.2174/1570159X1201140117162802.
- Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology--clinical practice guidelines for developing a diabetes mellitus comprehensive care plan--2015--executive summary. Endocr Pract. 2015;21:413-37. doi: 10.4158/EP15672.GL.
- Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a doubleblind, placebo-controlled trial. Pain. 2004;110:628-38. doi: 10.1016/j.pain.2004.05.001.
- Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-60. doi: 10.1016/j.jpain.2004.12.007.
- Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr.Pregabalin for relief of neuropathic pain associated with diabetic neuropathy:a randomized, double-blind study. Eur J Pain. 2008;12:203-13. doi: 10.1016/j.ejpain.2007.05.003.
- Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon MH, et al.Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32:2370-85. doi: 10.1016/j.clinthera.2011.01.014.
- Park JH, Won JC. Patterns of nerve conduction abnormalities in patients with type 2 diabetes mellitus according to the clinical phenotype determined by the current perception threshold. Diabetes Metab J. 2018;42:519-28. doi: 10.4093/dmj.2018.0068. Erratum in: Diabetes Metab J. 2019;43:381.
- Park KS, Kwon YC, Youn M, Park YS, Hong YH, Sung JJ. Current perception threshold in diabetic sensory polyneuropathy with normal routine nerve conduction study. Ann Clin Neurophysiol. 2017;19:125-30. doi: 10.14253/acn.2017.19.2.125.
- Prendergast JJ, Miranda G, Sanchez M. Improvement of sensory impairment in patients with peripheral neuropathy. Endocr Pract. 2004;10:24-30. doi: 10.4158/EP.10.1.24